A study of 41 adults with X-linked agammaglobulinemia found that most can function as relatively healthy individuals despite chronic, low-grade infections. Patients reported good health and quality of life, with many working full-time or attending school.
Researchers at St. Jude Children's Research Hospital have made significant progress in treating Acute Lymphoblastic Leukemia (ALL), with a reported 90% cure rate. The improvements are attributed to the effective use of existing drugs, genetic technologies, and personalized treatments.
Researchers found that the loss of caspase-8 protein promotes neuroblastoma metastasis by allowing cancer cells to break away from the primary tumor and spread to other sites in the body. Novel treatments that restore the tumor-suppression role of caspase-8 may prevent metastases and improve patient outcomes.
Researchers at St. Jude Children's Research Hospital have developed an antibody therapy that successfully targets and kills cancer cells in laboratory models of neuroblastoma. The treatment, which combines antibodies with immune system cells, has shown promise for treating low initial tumor levels or small cancer cell populations.
Researchers discovered that TRAF3 is essential for producing type I interferons and IL-10, a protein preventing inflammation. Cells lacking TRAF3 over-produce inflammatory proteins, highlighting its role in controlling the immune response to viruses.
Research at St. Jude Children's Research Hospital found that cocaine exposure alters brain chemistry, making neurons more susceptible to damage from environmental toxins. The study suggests a potential link between cocaine use and the development of Parkinson's disease in both adults and their offspring.
A new clinical trial found that using minimal residual disease (MRD) measurements, doctors can accurately assess treatment response and adjust therapy, leading to a high remission rate and low treatment-related mortality. This breakthrough approach improved outcomes for pediatric AML patients by identifying slow responders and intensif...
The Scythe protein is essential for normal lung, kidney, and brain development in embryos, and its absence leads to severe abnormalities. Understanding Scythe's function could provide insights into organ development and potentially lead to new treatments.
Researchers at St. Jude Children's Research Hospital discovered that histone deacetylase enzymes cooperate with CBP/p300 histone acetylases to trigger expression of genes responding to hypoxia. The study suggests that developing new therapies targeting both mechanisms may enhance treatment efficacy for solid tumors.
A study by St. Jude Children's Research Hospital suggests that mutations in the p53 protein may link to cancer, particularly adrenocortical carcinoma, while also forming disease-causing amyloid fibrils linked to Alzheimer's and Parkinson's diseases.
Studies using a laboratory model of PRODH deficiency demonstrate the role of COMT in compensating for overactive dopamine signaling, which contributes to schizophrenia symptoms. The findings show that disruptions in gene interaction, particularly between PRODH and COMT, play a crucial role in the development of schizophrenia.
Researchers at St. Jude Children's Research Hospital identified Cbln1 as a key protein maintaining correct synaptic connections in the adult brain. Without Cbln1, synapses weaken and new nerve connections form, disrupting brain function.
The study found that the absence or presence of the Ink4c gene can help predict patient outcomes for medulloblastoma. Additionally, the collaboration between Ink4c and Ptch1 genes demonstrates the importance of gene dosage in mediating protective effects against tumorigenesis.
Researchers identified distinct genetic signatures and cancer stem cell populations driving different subtypes of ependymomas. These findings suggest individualized treatment approaches targeting specific cancer stem cell populations could improve outcomes for patients with these tumors.
A new treatment approach using topotecan and carboplatin eliminates the need for etoposide, reducing the risk of leukemia. The study also suggests that vincristine contributes little to treating retinoblastoma, making it a promising alternative.
The study reveals that proteins RPL26 and nucleolin control p53 production in response to DNA damage. Increasing p53 function may boost radiation therapy effectiveness, while reducing it could protect normal cells from oxidative stress.
Despite over 100,000 research papers on apoptosis, the process remains unclear due to numerous signaling pathways involved. The 'upstairs/downstairs' model proposes critical steps occur before and after mitochondria breakdown, but identifying key pathways is crucial for developing effective treatments.
Children with advanced cancer can make informed decisions about their treatment, prioritizing the needs of others. The study found that 95% of participants cited caring for others as a factor in their decision-making, highlighting the importance of relationship-based end-of-life care.
The study found that suppression of the FOXO1a gene is necessary for ARMS cells to survive and avoid programmed cell death. The researchers believe that targeting this gene could lead to effective treatment options for children with ARMS tumors.
A laboratory model with defective lymphatic vessels has been found to exhibit abnormal fat accumulation and obesity in adulthood. The researchers discovered that adipocytes near leaking lymphatic vessels can store more lipids, leading to increased fat storage and subsequent obesity.
Analysis of M2 protein sequence data reveals higher resistance to antiviral drug amantadine in Southeast Asian H5N1 viruses, especially in China. This suggests selective pressure may be driving the emergence of resistant strains through human activities.
The PUMA protein coordinates the cell-suicide activities of p53 in the nucleus and cytoplasm. Researchers discovered that PUMA frees p53 from Bcl-xL, triggering a series of signals on mitochondria that leads to apoptosis. This finding solves the puzzle of why p53 activity occurs in both the nucleus and cytoplasm during apoptosis.
A study of 259 children undergoing bone marrow transplantation found that tooth decay was the most common dental problem, often caused by neglected oral hygiene and poor nutrition. Children with dental abnormalities were more likely to develop therapy-related caries if they underwent immunosuppression as part of their treatment.
A large study found that young children with medulloblastoma are at risk of impaired reading skills after radiation therapy, even if they receive lower doses. The greatest decline in IQ and reading skills occurred in patients younger than 7 years old.
Researchers discovered that Arf gene restricts blood vessel growth in the eye during embryonic development, preventing excessive growth and associated cancers. This finding may lead to new therapies for persistent hyperplastic primary vitreous and anticancer drugs.
A minimally invasive core-needle biopsy guided by CT scans or ultrasound appears to be an effective way to obtain tumor samples, replacing surgery. The technique shows high accuracy rates for diagnosing childhood cancers, with a sensitivity of 97% and specificity of 100%, according to St. Jude Children's Research Hospital researchers.
Researchers found that NIPA levels act as a switch to regulate cell division by degrading cyclin B1 during the 'resting' phase. Blocking NIPA causes premature cell division, leading to unhealthy daughter cells. The study sheds light on the role of SCFNIPA in controlling mitosis.
Vinculin and alpha-actinin work together to reinforce the cell skeleton, allowing it to withstand stress during movement and enabling purposeful motion. This discovery could help understand embryonic development and cancer metastasis.
Researchers successfully treated a laboratory model of GM1 – gangliosidosis using genetically modified bone marrow cells that produce an enzyme breaking down excess GM1. The treatment restored the activity of degenerating brain cells, suggesting a potential cure for this neurodegenerative disease.
Fine-tuning drug levels in neuroblastoma patients can improve treatment outcomes, according to St. Jude researchers. By closely monitoring and adjusting topotecan levels, the study demonstrates that pharmacokinetic-based dosing can tailor cancer treatment to individual children, potentially increasing long-term survival rates.
The extension study found that oral liquid hydroxyurea was well-tolerated in babies and worked similarly to older children, increasing fetal hemoglobin levels and preventing sickle cell complications. The treatment may also improve quality of life for patients with sickle cell anemia, especially in underprivileged areas.
The lack of effective cancer therapy access in developing countries is a pressing issue, with over 60% of children lacking treatment options. Experts propose twinning partnerships between institutions to improve pediatric cancer care through education and training.
Researchers found that blocking the Odc gene with the drug DFMO prevents cancer development in laboratory models, including lymphoma. The study suggests that a similar approach might prevent or slow cancer development in other types of cancer.
Researchers have developed a humanized mouse model that can produce functional white blood cells, allowing for studies of immune responses against cancer and infection. The model, called NOD-scid IL2Rãnull, combines characteristics of previous models to enable successful engraftment and development of an intact human immune system.
The FDA approved clofarabine for pediatric patients with relapsed or refractory ALL, built on years of effective use of pre-1980 drugs and adaptable for adult use later. Researchers say this approval is crucial for giving children access to new anti-cancer drugs.
Researchers identified 45 genes linked to leukemic cells' ability to resist treatment by at least two of the most widely used antileukemic drugs. The study found a poor prognosis for patients with cross-resistant ALL cells.
Researchers at St. Jude Children's Research Hospital have developed a technique to produce large numbers of genetically modified NK cells that can effectively target and eliminate leukemia cells. The new technology has the potential to be used as a treatment for leukemia patients undergoing hematopoietic cell transplantation.
The TEL2 gene cooperates with MYC to increase the risk of precancerous B lymphocytes becoming cancerous. This cooperation leads to a mutation inactivating p53, allowing abnormal cells to multiply uncontrollably. The study suggests that TEL2 should be considered a diagnostic marker and/or a target for novel drugs to treat B-cell lymphoma.
A new study from St. Jude Children's Research Hospital found that both inherited genetic traits and tumor mutations can affect the response to treatment of leukemia. The research identified specific genes, such as GSTM1 and TYMS, that predict which children are at higher risk of relapse after initial therapy.
St. Jude Children's Research Hospital finds that upfront treatment with radiation followed by chemotherapy can cure brain tumors in children over 3 years old, raising survival rates to 78% for two-year event-free survival and 89% for overall survival. The study shows promise for treating relapse cases using ICE chemotherapy.
The study shows that blocking CK2 activity makes cancer cells sensitive to TRAIL-induced apoptosis, a promising strategy for treating colorectal cancer and other solid tumors. Researchers used a CK2-inhibitor or short hairpin RNA to block CK2 activity, sensitizing cancer cells to TRAIL and inducing cell death.
A new study reveals that Mcl-1 protein is essential for the survival of hematopoietic stem cells (HSCs), which can contribute to poor leukemia outcomes. The research suggests that interfering with this protein may improve leukemia treatment options.
The level of signal-joint TRECs (sjTRECs) in the blood appears to directly reflect the ability of the transplant recipient's thymus gland to process donated stem cells. High levels of sjTRECs indicate a successful reconstitution of the T cell population, improving patient outcomes.
The St. Jude team determined the shape of CbpA, a large protein used by Streptococcus pneumoniae bacteria to invade human cells. This discovery will guide researchers in developing a new vaccine that can trigger production of antibodies against the CbpA protein.
The guidelines provide recommendations for screening and management of late effects in pediatric cancer survivors, aiming to improve adult quality of life. The report authors anticipate that widespread use will help researchers determine the efficacy of screening survivors to reduce medical complications and death.
Researchers have developed a new mouse model of Leber congenital amaurosis, a rare form of childhood blindness. The model, which lacks the AIPL1 gene, closely mimics the inherited human disease and shows severe retinal degeneration starting around two weeks of life.
A three-week treatment with methylphenidate improved the attention and behavioral problems of children who survived childhood cancer, including leukemia and brain tumors. The study suggests that this treatment may help resolve some of the serious side effects of cancer treatment in these children.
Researchers at St. Jude Children's Research Hospital found that white matter lesions caused by treatment can mimic cancer, leading to unnecessary treatment. The study also linked WMLs to a decline in neurocognitive function in children with brain tumors.
The program will test 10-15 drugs or drug combinations per year to identify promising agents for childhood cancer treatment. It uses preclinical models and genetically engineered lines to predict activity and extends previous research by testing a broader spectrum of anticancer agents.
A St. Jude clinical trial has shown promising results in treating acute lymphoblastic leukemia with a new chemotherapy regimen that eliminates irradiation, achieving high event-free survival rates of over 80% and overall survival rates of around 86%. The trial's stringent risk classification and early intensification of chemotherapy le...